Creating a better bioeconomy with innovative genome technologies.

OriCiro is a pioneer of cell-free genome technology, providing a powerful tool for research and development aimed at unlocking the possibility of synthetic biology. The company focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules. One of the company’s proprietary technologies enables cell-free amplification of large DNA molecules, an efficient and easy-to-operate approach that aims to replace the conventional cell-based methodology. It can not only streamline current research processes but also widen the scope of genomics research significantly. In addition to the amplification technology, the company owns a suite of genome technologies, including the assembly of DNA fragments and genome editing. Synthetic biology — an emerging field in life sciences in which new medicines and useful proteins can be produced more efficiently by modified and/or synthesized genomes — is developing rapidly worldwide with ever-increasing industrial applications. OriCiro’s technologies have potential markets in a variety of industries including the pharmaceutical, diagnostic, industrial biotech, food, and agricultural sectors.

FOUNDED
2018

HEADQUARTERS
Tokyo, Japan

COMPANY SIZE
1–5

Seiji Hirasaki

Seiji Hirasaki (CEO at OriCiro) has been an Unreasonable Fellow since September 2019 after participating in Unreasonable Impact Asia Pacific 2019.

Unreasonable Impact Asia Pacific 2019

Connect with OriCiro

Follow OriCiro on social media below.

  • Featured VentureAeroFarms

  • Featured VentureElvis & Kresse